Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

A streamlined base editor reengineering platform to enhance gene editing specificity and selectivity

Award Number: R33HL185498
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/01/2026
PERIOD OF PERFORMANCE END DATE: 04/30/2028

Group Awards By:

View Award Description

A streamlined base editor reengineering platform to enhance gene editing specificity and selectivity - PROJECT SUMMARY Base editing (BE) can permanently correct over half of known human pathogenic genetic variants without requiring a repair template, thus serving as a promising therapeutic tool to treat a broad spectrum of genetic diseases. However, the broad activity windows and substantial off-target activities of current base editors pose a major challenge to their therapeutic application. Current methods to improve base editing specificity rely on large-scale saturation mutagenesis of the key residues involved in substrate interactions, which can be labor- intensive and time-consuming. The main goal of this project is to establish a streamlined base editor engineering platform to accelerate the development of therapeutic base editing. Recently, we developed a base editor re- engineering strategy by integrating a naturally occurring oligonucleotide binding module into the deaminase active center to enhance its editing specificity. Preliminary editing studies demonstrate that this engineering platform yielded a suite of base editors (iBEs) with refined activity windows and decreased off-target activities, enabling versatile yet precise single-nucleotide conversions. Encouragingly, iABE outperforms all the existing ABEs in correcting one of the most common CFTR nonsense mutations. Building upon this work, we will further advance this base editor re-engineering platform to develop base editors with minimized off-target activities and programmable editing selectivity, and assess its broad application in directing the evolution of alternative deaminases with enhanced specificity (Aim 1). Further, we will validate the editing efficiency, specificity, and outcomes of iBEs in correcting diverse CFTR nonsense mutations in cystic fibrosis cell and animal models (Aim 2). Successful completion of this project will provide a roadmap for designing and engineering therapeutic base editors for correcting disease-causing point mutations and establish a lung-targeted gene correction toolkit tailored for CF, laying the groundwork for future CF gene therapy development.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $570,666 )
2026	2026	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	1 GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Lung Diseases Research	000	1	6/23/2026	NEW	$570,666
														Subtotal = $570,666

Grand Total All Awards = $570,666

Top

All Categories

About

Search

Reports

Data Submission

Award Information

A streamlined base editor reengineering platform to enhance gene editing specificity and selectivity

Award Number: R33HL185498

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/01/2026

PERIOD OF PERFORMANCE END DATE: 04/30/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer